<DOC>
	<DOCNO>NCT01573286</DOCNO>
	<brief_summary>This protocol outline randomize , open label trial examine safety , pharmacology efficacy Glucagon like peptide 2 ( GLP-2 ) infants child intestinal failure . The investigator hypothesize GLP-2 give subcutaneously patient well tolerate , similar metabolism show adult . The investigator also expect show improvement tolerance enteral nutrition , decrease requirement intravenous feeding .</brief_summary>
	<brief_title>Safety Dosing Study Glucagon-like Peptide 2 ( GLP-2 ) Infants Children With Intestinal Failure</brief_title>
	<detailed_description>GLP-2 ( 1-33 ) naturally occur peptide important control function intestine . In previous study group show serum level GLP-2 correlate intestinal function human neonate . Low level GLP-2 predictive intestinal malabsorption development call `` Short Bowel Syndrome '' . GLP-2 show specifically trophic GI tract , especially small intestine . This proposal outline Phase 1 2 trial use subcutaneous administration , twice daily GLP-2 human infant child Intestinal Failure , typically Short Bowel Syndrome , use vary dos , assign prospective , randomize protocol , open label monitoring . The investigational plan begin Phase 1 trial , administer GLP 2 varying dos ( infant assign dos 5,10 , 20 μg/kg/day , child great 1 year dose 20 μg/kg/day , give via twice daily subcutaneous injection ) . Eligible subject infant ( less 12 month correct gestational age ) either major resection ( remain small intestine le 40 % predict length gestational age ) , demonstrate intestinal failure intestinal resection/abdominal surgery/gastroschisis ( Requirement parenteral nutrition great 50 % total calorie , 45 day last surgery ) . Infants allocate sequentially group ( n = 6 per group ) treat GLP-2 5,10 , 20 μg/kg/day . Older child ( great 1 year age ) , require PN &gt; 30 % calorie &gt; one year post surgery also eligible ; patient dose 20 μg/kg/day ( via twice daily subcutaneous injection ) n= 7 . Patients follow principle intention treat initial randomization . The endpoint monitor safety , record adverse event pharmacokinetic profile 3 day . If hormone well tolerated study extend phase 2 study , additional 39 day ; monitor safety , patient tolerance enteral nutrition , growth , citrulline level , nutrient absorptive capacity , liver function repeat pharmacokinetic study .</detailed_description>
	<mesh_term>Short Bowel Syndrome</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>Infants ( &lt; 1 year correct gestational age ) Infants congenital anomaly , intestinal resection , leave anatomic short bowel syndrome ( total remain small intestine le 40 % predict gestational age ) eligible treatment immediate postoperative period . Infants intestinal resection repair gastroschisis demonstrate dependence parenteral nutrition 45 day post operation requirement &gt; 50 % calorie PN ( independent length remnant small intestine ) . Children ( &gt; 1 year correct gestational age ) Children requirement &gt; 30 % calorie PN 1 year ( 365 ) day post surgery eligible . Significant extraintestinal disease ( e.g. , grade IV intraventricular hemorrhage , severe hypoxic encephalopathy ) ; Significant cardiovascular , hemodynamic respiratory instability , note 1 ) requirement dopamine &gt; 4 mcg/kg/min , 2 ) high frequency ventilatory support , 3 ) extracorporeal membrane oxygenation . Hepatic disease define direct bilirubin &gt; 100 umol/L ( 5.2 mg/dL ) Renal disease define BUN &gt; 80 creatinine &gt; 90 μmol/L ( 1.5 mg/dL ) Inborn error metabolism necessitate protein restriction special diet ; Ongoing sepsis syndrome , note refractory hypotension , thrombocytopenia , acidosis , and/or bacteremia . Primary motility defect intestinal pseudoobstruction . Absorptive defect ( microvillus inclusion disease ) Females postpubertal must agree comply measure prevent pregnancy study phase . Coagulopathy precludes use subcutaneous injection . Allergy GLP2 constituent GLP2 IC115 preparation .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Infant Nutrition Disorders</keyword>
	<keyword>Childhood nutrition disorder</keyword>
	<keyword>malnutrition</keyword>
	<keyword>post surgical syndrome</keyword>
	<keyword>necrotising enterocolitis</keyword>
	<keyword>intestinal atresia</keyword>
	<keyword>gastroschisis</keyword>
</DOC>